Sign inJoin waitlistJoin the waitlist

Kathryn Hourdequin

Assistant Professor of Medicine · Geisel School of Medicine

Credentials: · · · · · · ·

History

Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital Fellowship
Present
Dartmouth-Hitchcock Fellowship
Present
Geisel School of Medicine
Present

Medical Oncology
2012–2014
Dartmouth Hitchcock Medical Center
2011–2012
Dartmouth Cancer Center
2000–2003
Yale Univ Sch of Med
1996–2000
Harvard University

Research

Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations
Clinical Chemistry · 2014 · 75 citations
Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis
Systematic review or meta-analysis · Annals of Oncology · 2013 · First of 5 authors · 63 citations
Merkel cell polyomavirus and extrapulmonary small cell carcinoma
Oncology Letters · 2013 · First of 6 authors · 11 citations

Gregory Ripple
4 papers
Gabriel Brooks
3 papers
Manik Amin
3 papers
Bassem Zaki
2 papers
GT
Gregory Tsongalis
2 papers
JP
J. Pipas
2 papers
Kerrington Smith
2 papers
Konstantin Dragnev
2 papers
Alexander Fuld
1 paper
Arief Suriawinata
1 paper
DD
Devanshi Dove
1 paper · 1 as a fellow
Heather Wright
1 paper

Clinical trials

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2023–2032
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2022–2027
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2021–2027
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2020–2027